Is universal antifungal prophylaxis mandatory in adults after lung transplantation? A review and meta‐analysis of observational studies
- 25 October 2016
- journal article
- review article
- Published by Wiley in Clinical Transplantation
- Vol. 30 (12), 1522-1531
- https://doi.org/10.1111/ctr.12854
Abstract
Lung transplant (LTX) recipients are at high risk of invasive Aspergillus infections (IAI). However, no randomized-controlled trials (RCT) or international guidelines on antifungal prophylaxis (AFP) in the LTX population exist. A meta-analysis was performed to determine whether AFP reduces the rate of IAI after LTX. A total of six eligible observational studies (five with no prophylaxis, one with targeted prophylaxis, three studies including heart/lung transplantation) with a total of 748 patients were included. The pooled odds ratio (OR) for IAI (62 IFI in the intervention arm and 82 in the control group) was 0.234 (95% confidence interval [CI] 0.097-0.564, P=0.001, z=−3.237). Pooled studies were characterized by substantial heterogeneity (I2=66.64%); number needed to treat was 6.8. A subgroup analyses with exclusion of heart transplant recipients also showed a statistically significant reduction in IAI with AFP (OR 0.183, 95% CI 0.0449-0.744, P=0.018). This study suggests that universal antifungal prophylaxes reduces incidence of IAI after LTX. However, included studies are limited by small sample size, single-center structure without randomization, mixed population (including heart/heart-lung transplant), and heterogeneity due to variations in immunosuppression, type, and duration of AFP. Therefore, there is a clear need for an adequately powered RCT.Keywords
This publication has 44 references indexed in Scilit:
- Aspergillosis in Solid Organ TransplantationAmerican Journal of Transplantation, 2013
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantationThe Journal of Heart and Lung Transplantation, 2010
- 573: Is Targeted Antifungal Prophylaxis Effective in Lung Transplants?The Journal of Heart and Lung Transplantation, 2010
- Antifungal Prophylaxis with Voriconazole or Itraconazole in Lung Transplant Recipients: Hepatotoxicity and EffectivenessAmerican Journal of Transplantation, 2009
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008
- 178: Effect of antimycotic prophylaxis with itraconazol and voriconazol in patients following lung transplantationThe Journal of Heart and Lung Transplantation, 2006
- Itraconazole Prophylaxis in Lung Transplant Recipients Receiving Tacrolimus (FK 506): Efficacy and Drug InteractionThe Journal of Heart and Lung Transplantation, 2005
- Review of patient outcomes of aspergillus prophylaxis with voriconazole after lung transplantationThe Journal of Heart and Lung Transplantation, 2005
- Pre-emptive therapy with azoles in lung transplant patientsEuropean Respiratory Journal, 1999